Status:
COMPLETED
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Lead Sponsor:
Bayer
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
45+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsal...
Eligibility Criteria
Inclusion
- Participants must be 45 years of age or older, at the time of signing the informed consent
- Acute myocardial infarction (excluding MI associated with PCI or CABG revascularization procedures) with:
- clinical symptoms of acute myocardial infarction AND
- elevated biomarkers of myocardial necrosis (creatine kinase-muscle and brain isoenzyme \[CK-MB\] or cardiac troponins) AND
- at least one of the following risk factors need to be fulfilled:
- Age ≥ 65 years
- Prior MI (before the index AMI event)
- Prior peripheral arterial disease
- Diabetes Mellitus
- Prior coronary artery bypass grafting (CABG) AND
- initial angiography and revascularization procedures, either PCI or CABG, as treatment for the index event performed before randomization. (Note: a planned, staged PCI procedure can be performed after randomization)
- Plan for dual antiplatelet therapy (ASA + P2Y12 inhibitor) after hospital discharge for the index AMI
- Randomization during hospitalization for the index AMI event and latest within 5 days of hospital admission
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent has to be signed before any study-specific procedure.
Exclusion
- Hemodynamically significant ventricular arrhythmias or cardiogenic shock at time of randomization
- Active bleeding; known bleeding disorder, history of major bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months of randomization
- Planned use or requirement of full dose and long term anticoagulation therapy during study conduct.
Key Trial Info
Start Date :
June 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2022
Estimated Enrollment :
1601 Patients enrolled
Trial Details
Trial ID
NCT04304534
Start Date
June 17 2020
End Date
February 21 2022
Last Update
April 5 2023
Active Locations (160)
Enter a location and click search to find clinical trials sorted by distance.
1
Valley Clinical Trials, Inc. - Covina
Covina, California, United States, 91723
2
Florida Premier Cardiology
Boynton Beach, Florida, United States, 33437
3
Clearwater Cardiovascular Associates | Clearwater, FL
Clearwater, Florida, United States, 33756
4
Cardiology Associates Research Company
Daytona Beach, Florida, United States, 32117